Showing 5411-5420 of 7686 results for "".
- More Positive Upadacitinib Data Presentedhttps://practicaldermatology.com/news/more-positive-upadacitinib-data-presented/2467018/New data presented at the Revolutionizing Atopic Dermatitis (RAD) Conference from June 8-10 in Chicago, Illinois, built on previously published top-line results comparing upadacitinib to dupilumab by demonstrating superiority for all ranked secondary endpoints at varying response levels and time
- Parental E-Cigarette Use Linked to Pediatric ADhttps://practicaldermatology.com/news/parental-e-cigarette-use-linked-pediatric-ad/2467003/Electronic cigarette use by parents is associated with increased chances of pediatric atopic dermatitis, according to an article published last month by JAMA Dermatology. In a retrospective cross-sectional analysis of the 2014 to 2018 National Health Interview Survey, researchers found tha
- FDA Takes Key Step on Tapinarof for ADhttps://practicaldermatology.com/news/fda-takes-key-step-tapinarof-ad/2467002/The US Food and Drug Administration has accepted a supplemental new drug application for Dermavant’s VTAMA (tapinarof) following positive results of a Phase III clinical trial for the drug’s use on atopic dermatitis patients 2 and older, according to GlobalData. Tapinarof, an aryl hydrocar
- Study: Some Permanent Makeup May Cause Allergic Contact Dermatitishttps://practicaldermatology.com/news/study-some-permanent-makeup-may-cause-allergic-contact-dermatitis/2467001/Like tattoos, some permanent makeup products contain pigments known to cause allergic contact dermatitis, according to a Journal of the American Academy of Dermatology (JAAD) study published May 31, 2024. The study, titled “Identification of the Pigments Used in Permanent Makeup and Their
- Tirbanibulin Approved for Actinic Keratosishttps://practicaldermatology.com/news/tirbanibulin-approved-actinic-keratosis/2466999/The U.S. Food and Drug Administration (FDA) has approved tirbanibulin (Klisyri, Almirall) for the treatment of actinic keratosis on an expanded area of the scalp and face, according to a news release from the manufacturer. The tirbanibulin ointment, 1% is a microtubule inhibitor with a f
- FDA Approves First Eyedrops to Treat Mites Living on Eyelasheshttps://practicaldermatology.com/news/fda-approves-first-eyedrops-treat-mites-living-eyelashes/2466993/FDA Approves First Eyedrops to Treat Mites Living on Eyelashes More than 25 million Americans are living with Demodex blepharitis, an underdiagnosed condition that involves mites living on a person’s eyelashes. Demodex blepharitis has gone underdiagnosed for decades because of a l
- Study: Sodium Levels Linked to Atopic Dermatitishttps://practicaldermatology.com/news/study-sodium-levels-linked-atopic-dermatitis/2466978/High sodium levels could be linked to increased risk of developing atopic dermatitis, according to a JAMA Dermatology study published June 5. A cross-sectional study of 215,832 adults found that a 1-g higher estimated 24-hour urine sodium excretion was associated with 11% higher odds of at
- Lebrikizumab Maintains Efficacy Through 52 Weekshttps://practicaldermatology.com/news/lebrikizumab-maintains-efficacy-through-52-weeks/2466977/New data from a pooled analysis of the ADvocate1 and ADvocate2 trials indicates lebrikizumab was efficacious for treating atopic dermatitis (AD) over a year-long period. “Lebrikizumab demonstrated significant improvement versus placebo for measures of skin clearance and patient reported ou
- Study Highlights Gaps in Dermatology PA Certification Exam Coveragehttps://practicaldermatology.com/news/research-highlights-gaps-dermatology-pa-certification-exam-coverage/2466960/New research suggests that the prevalence of skin disease burden in the United States generally aligns with the physician assistant (PA) certification exam, with areas for improvement. According to the new study published in the Journal of Dermatology Physicians Assistants, the National C
- Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areatahttps://practicaldermatology.com/news/equillium-announces-positive-topline-data-phase-2-study-eq101-alopecia-areata/2466936/Equillium announced positive topline data from its phase 2, single dose, proof-of-concept (PoC) study of EQ101 in adult patients with moderate, severe or very-severe alopecia areata (AA). The primary objectives of the study were to evaluate the safety and tolerability profile of EQ101, as well as